Engelsk titel: Treatment of ischemic heart disease with the platelet aggregation inhibitor clopidogrel
Läs online
Författare:
Helö OH
;
Kyst Madsen J
;
Kastrup J
Email: jkastrup@rh.dk
Språk: Dan
Antal referenser: 17
Dokumenttyp:
Översikt
UI-nummer: 04051145
Sammanfattning
Clopidogrel is a new platelet aggregation inhibitor that is just as effective as Aspirin in secondary prophylaxis in ischemic heart disease. However, Aspirin is still the primary treatment recommendation for secondary prophylaxis in ischemic heart disease. As prophylaxis for acute in-stent thrombosis after percutaneous coronary intervention with stent implantation, the combination of Aspirin and clopidogrel for 12 months is now recommended. Patients with acute non-ST-segment-elevating coronary syndrome should be treated with early initiation of clopidogrel treatment, which should be continued for at least nine months. However, most of these patients will receive 12 months of clopidogrel treatment after PCI with stent.